PML/RARA - t(15;17) Qualitative by PCR Test

This test detects the PML/RARA fusion gene, which is essential for diagnosing and monitoring acute promyelocytic leukaemia (APL). The presence of this fusion gene leads to an abnormal cell growth and help determine the presence of APL.

• To diagnose or confirm acute promyelocytic leukaemia
• To monitor the effectiveness of treatment and detect disease recurrence
• To guide appropriate therapy decisions and assess prognosis

The PML/RARA - t(15;17) Qualitative by PCR Test is recommended:

• If you have symptoms like easy bruising, bleeding, or recurrent infections
• If  your blood counts are abnormal or if a haematological disorder is suspected
• If your doctor wants to confirm APL diagnosis, monitor response to treatment, or assess residual disease after therapy

• Abnormal results indicate presence of PML/RARA, which may indicate acute promyelocytic leukaemia
• Follow-up testing, consultation with a haematologist, and further evaluation are necessary

• A blood sample is collected from a vein in your arm using a needle
• The sample is sent to the laboratory for analysis using PCR technology

• Follow your doctor's instructions
• Inform your doctor about any medications you are taking that might affect the test results

• FISH (Fluorescent In Situ Hybridisation): To identify specific genetic abnormalities
• Bone Marrow Aspiration/Biopsy: To evaluate bone marrow health
• Complete Blood Count (CBC): To assess blood cell levels

PCR Test for Acute Promyelocytic Leukaemia or PML-RARA Qualitative Test

APL is a type of blood cancer where immature white blood cells accumulate and disrupts normal blood cell production. The disease is characterised by the presence of PML/RARA fusion gene, requiring accurate diagnosis and prompt treatment for effective management